-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022(NYSE American: SYN), a diversified
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive.
To increase the adenovirus-based oncolytic products, it is essential to select the right candidate. The characterization and manufacturing process needs to be scalable up to bigger batches than intratumoral administration. Also, the regulatory environment is different for intratumoral and intravenous administration, as different amounts of impurities are accepted, so these need to be eliminated. In addition, platform selection is critical.
-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel.
/PRNewswire/ Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in.